期刊文献+

缬沙坦对高血压合并糖尿病患者血压及血管内皮功能的影响 被引量:3

Effect of valsartan on endothelium-dependent relaxing function in hypertensive patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的:研究缬沙坦对原发性高血压合并2型糖尿病患者血压及血管内皮依赖性舒张功能的影响。方法:23例高血压合并2型糖尿病患者服用缬沙坦片80-160mg/d,测定治疗前及治疗后3、6个月体重指数(BMI)、总胆固醇(TC)、甘油三酯(TG)、空腹血糖(FBG)、餐后2h血糖(2h-PBG)、收缩压(SBP)、舒张压(DBP)及右肱动脉内径基础值(D0)和反应性充血、含服硝酸甘油后右肱动脉内径的变化率(△D1、△D2),并对治疗前后各指标的变化进行了比较。结果:(1)治疗后3、6个月与治疗前相比,BMI、TC、TG、FBG、2h-PBG均无明显变化(P均>0.05)。(2)治疗后3、6个月SBP、DBP均较治疗前明显降低(P均<0.01),而治疗后6个月与3个月相比,血压降低更为明显(P<0.05)。(3)治疗后3、6个月反应性充血后右肱动脉内径变化率均较治疗前明显改善(P均<0.05),但治疗后6个月较3个月无进一步改善。结论:缬沙坦治疗原发性高血压合并2型糖尿病在降压同时可有效改善血管内皮依赖性舒张功能,且降压效果呈现时间依赖性。 Objective: To investigate the effect of valsartan on blood pressure and endothelium-dependent relaxing function in essential hypertensive patients with type 2 diabetes mellitus. Methods: We measured body mass index(BMl), total cholesterol(TC), triglyceride(TG), fasting blood glucose(FBG), postprandial blood glucose(2 h-PBG), systolic blood pressure(SBP), diastolic blood pressure (DBP) and fundamental inner diameter of brachial arteries(D0), diameter in brachial arteries in responding to reactive hyperaemia and after suming glyceryltrinitrate(△D1 , △D2)of 23 essential hypertensive patients with type 2 diabetes mellitus before and after treated withvalsartan80-160 mg/d for 3 and 6 months. Results: (1) After treatment, BMI, TC, TG, FBG, 2 h-PBG showed no marked change. (2) After treatment for 3, 6 months, SBP and DBP were all cut down obviously than before, and that of 6 months gained further degrade than 3 months. (3) After 3, 6 months, AD1 were improved greatly than before treatment, but after 6 months had no obvious amendment than that after 3 months. Conclusions: Valsartan may improve endothelium-dependent vasodilation in hypertensive patients with type 2 diabetes mellitus besides antihypertension therapy, and the effect of depressurization seems to be time-dependent.
出处 《新疆医科大学学报》 CAS 2005年第9期835-837,共3页 Journal of Xinjiang Medical University
关键词 缬沙坦 高血压 2型糖尿病 内皮依赖性血管舒张 valsartan hypertension type 2 diabetes mellitus endothelium-dependent vascular vasodilation
  • 相关文献

参考文献9

  • 1Furuta M, Tsunoda K, Arita M, et al. Endothelium-dependent vasodilation in type II diabetes mellitus[J]. Rinsho Byori, 2003, 51(11): 1111-1115.
  • 2Modan M, Halkin H, Alnong S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance[J]. Clin Invest, 1995,75:809.
  • 3WHO/ISH Guidelines Committee. 1999 World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension [J]. Blood Press, 1999,(1 Suppl):9-43.
  • 4The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus[J]. Diabetes Care, 1997,20: 1183-1197.
  • 5Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfuntion in children and adults at risk of atherosclerosis[J]. Lancet, 1992, 340:1111-1115.
  • 6Kimura Y, Matsumoto M, Miyauchi E, et al. Noninvasive detection of endothelial dysfunction in elderly with NIDDM by ultrasonography[J]. Echocardiography, 2001,18:559-563.
  • 7Michael P, Malte K, Peter R, et al. Additive effect of coexistent type 2 diabetes and arterial hypertension on endothelial dysfunction in resistance arteries of forearm vascular[J]. Angiology,2000, 51(7):545-554.
  • 8Cheetham C, Collis J, O′Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes[J]. J Am Coll Cardiol, 2000, 36(5):1461-1466.
  • 9Kalinowski L, Matys T, Chabielska E, et al. Angiotensin Ⅱ AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release[J]. Hypertension, 2002, 40(4):521-527.

同被引文献27

  • 1Suzuki K, Aizawa Y. Evaluation of dosing time - related anti - hypertensive efficacy of valsartan in patients with type 2 di- abetes[J].Clin Exp Hypertens, 2011, 33(1): 56.
  • 2Luan FL. Effect of valsartan on the incidence of diabetes[J]. N Engl J Med, 2010, 363(8) : 792.
  • 3Kintscher U, Marx N, Martus P, et al. Effect of high- dose valsartan on inflammatory and lipid parameters in pa- tients with Type 2 diabetes and hypertension [J] Diabetes Res Clin Pract, 2010, 89(3) : 209.
  • 4Lee JM, Kim JH, Son HS, et al. Valsartan increases circu- lating adiponectin levels without changing HOMA IR in pa- tients with type 2 diabetes mellitus and hypertension[J]. J Int Med Res, 2010, 38(1): 234.
  • 5Weir MR, Hollenberg NK, Zappe DH, et al. Antihyperten- sive effects of double the maximum dose of valsartan in African - American patients with type 2 diabetes mellitus and albuminuria[J] J Hypertens, 2010, 28 ( 1 ) : 186.
  • 6Van der Niepen P, Woestertburg A, Bri H, et al. Effective- ness of valsartan for treatment of hypertension: patient profil- ing and hierarchical modeling of determinants and outcomes (the PREVIEW study) [J]. Ann Phamaacother, 2009, 43 (5) : 849.
  • 7Beloumv IuB, Shestakova MV, Belousov DIu. Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus[J]. Kardiologiia, 2008, 48(12) : 14.
  • 8Van Buren PN, Toto RD. The pathogenesis and management of hypertension in diabetic kidney disease[J]. Med Clin North Am,2013,97(1) :31- 51.
  • 9中国高血压防治指南修汀委员会.中国高札压防治指南[M].3版.北京:人民甲生出版社,2011:3.
  • 10Wu A, Kong NCT, deLeon F, et al. A prospeetive evaluation of mieroalbuminuria in hypertensive type 2 diabeties in Asia: the MAPS (mieroalbuminuria prevalenee) study[J]. Diabetolo- gia,2004,48(4) :17- 26.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部